Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Bioretec: RemeOs screw secures additional US reimbursement

Analyst Comment 10.11.2026 klo 09.21 by Antti Siltanen
Bioretec

Bioretec Q3'26 preview: Growth expected, but earnings still lagging

Analyst Comment 10.11.2026 klo 09.30 by Antti Siltanen
Bioretec

Herantis: Trial preparations progressing and production scaled up

Analyst Comment 06.11.2026 klo 10.16 by Antti Siltanen
Herantis Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account

Modulight receives new order in quantum technology

Analyst Comment 05.11.2026 klo 10.36 by Antti Siltanen
Modulight

Aiforia: Speculative play if you have an appetite for risk

Research 04.11.2026 klo 10.08 by Antti Siltanen, Antti Luiro
Aiforia Technologies

Biohit: Market in a gloomy mood

Research 04.11.2026 klo 10.43 by Antti Siltanen
Biohit

Modulight: Nascent growth at a reasonable price

Research 03.11.2026 klo 10.38 by Antti Siltanen
Modulight

Nightingale: Contracts keep flowing

Research 03.11.2026 klo 10.04 by Antti Siltanen, Antti Luiro
Nightingale Health

Nightingale’s deal flow keeps a healthy beat

Analyst Comment 29.10.2026 klo 09.05 by Antti Siltanen
Nightingale Health

Aiforia update: Foothold in the US market strengthens through the PathAI partnership

Video 26.10.2026 klo 15.45 by Antti Siltanen
Aiforia Technologies